Sympathetic activation secondary to chronic kidney disease: Therapeutic target for renal denervation?

Journal of Hypertension

Volumn 32, Issue 9, 2014, Pages 1751-1761

  De Beus, Esther ^a   De Jager, Rosa ^a   Joles, Jaap A ^a   Grassi, Guido ^b,c   Blankestijn, Peter J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c IRCCS MULTIMEDICA   (Italy)

Author keywords

chronic kidney disease; renal denervation; sympathetic activity

Indexed keywords

ALDOSTERONE ANTAGONIST; ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MOXONIDINE; RENIN; THIAZIDE DIURETIC AGENT;

BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; DIAGNOSTIC TEST; DORSAL RHIZOTOMY; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; KIDNEY DENERVATION; LIFESTYLE MODIFICATION; MORTALITY; NONHUMAN; PATHOGENESIS; PATIENT SELECTION; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYMPATHECTOMY; SYMPATHETIC FUNCTION; VASCULAR RESISTANCE; ADRENERGIC SYSTEM; CHRONIC KIDNEY FAILURE; COMPLICATION; INJURIES; KIDNEY; PATHOPHYSIOLOGY; PROCEDURES;

HUMANS; HYPERTENSION; KIDNEY; RENAL INSUFFICIENCY, CHRONIC; SYMPATHECTOMY; SYMPATHETIC NERVOUS SYSTEM;

EID: 84906099808     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000210     Document Type: Review

References (138)

1. Blankestijn PJ, Ritz E. Renal denervation: Potential impact on hypertension in kidney disease?. Nephrol Dial Transplant 2011; 26:2732-2734
2. Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 1999; 34 (4 Pt 2):724-728
3. Neumann J, Ligtenberg G, Klein II, Koomans HA, Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease: Pathogenesis, clinical relevance, and treatment. Kidney Int 2004; 65:1568-1576
4. Siddiqi L, Joles JA, Grassi G, Blankestijn PJ. Is kidney ischemia the central mechanism in parallel activation of the renin and sympathetic system?. J Hypertens 2009; 27:1341-1349
5. Vink EE, Blankestijn PJ. Evidence and consequences of the central role of the kidneys in the pathophysiology of sympathetic hyperactivity. Front Physiol 2012; 3:29
6. Vink EE, De Jager RL, Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease: Pathophysiology and (new) treatment options. Curr Hypertens Rep 2013; 15:95-101
7. Schlaich MP, Socratous F, Hennebry S, Eikelis N, Lambert EA, Straznicky N, et al. Sympathetic activation in chronic renal failure. J Am Soc Nephrol 2009; 20:933-939
8. Dibona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997; 77:75-197
9. Dibona GF. Neural control of the kidney: Past, present, and future. Hypertension 2003; 41 (3 Pt 2):621-624
10. Stella A, Zanchetti A. Functional role of renal afferents. Physiol Rev 1991; 71:659-682
11. Augustyniak RA, Picken MM, Leonard D, Zhou XJ, Zhang W, Victor RG. Sympathetic nerves and the progression of chronic kidney disease during 5/6 nephrectomy: Studies in sympathectomized rats. Clin Exp Pharmacol Physiol 2010; 37:12-18
12. Kottke FJ, Kubicek WG, Visscher MB. The production of arterial hypertension by chronic renal artery-nerve stimulation. Am J Physiol 1945; 145:38-47
13. Calaresu FR, Stella A, Zanchetti A. Haemodynamic responses and renin release during stimulation of afferent renal nerves in the cat. J Physiol 1976; 255:687-700
14. Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension 2004; 43:699-706
15. Campese VM, Kogosov E, Koss M. Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis 1995; 26:861-865
16. Ye S, Gamburd M, Mozayeni P, Koss M, Campese VM. A limited renal injury may cause a permanent form of neurogenic hypertension. Am J Hypertens 1998; 11 (6 Pt 1):723-728
17. Kopp UC. Neural control of renal function. San Rafael, CA: Morgan & Claypool Life Sciences; 2011
18. Kopp UC, Cicha MZ, Smith LA. Impaired responsiveness of renal mechanosensory nerves in heart failure: Role of endogenous angiotensin. Am J Physiol Regul Integr Comp Physiol 2003; 284:R116-R124
19. Kopp UC, Smith LA, Dibona GF. Impaired renorenal reflexes in spontaneously hypertensive rats. Hypertension 1987; 9:69-75
20. Kim KE, Onesti G, Schwartz AB, Chinitz JL, Swartz C. Hemodynamics of hypertension in chronic end-stage renal disease. Circulation 1972; 46:456-464
21. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327:1912-1918
22. Grassi G, Quarti-Trevano F, Seravalle G, Arenare F, Volpe M, Furiani S, et al. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension 2011; 57:846-851
23. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, jkhorst-Oei LT, Boomsma F, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340:1321-1328
24. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 2001; 12:2427-2433
25. Klein IH, Ligtenberg G, Neumann J, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol 2003; 14:3239-3244
26. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 2003; 14:425-430
27. Siddiqi L, Joles JA, Oey PL, Blankestijn PJ. Atorvastatin reduces sympathetic activity in patients with chronic kidney disease. J Hypertens 2011; 29:2176-2180
28. Siddiqi L, Oey PL, Blankestijn PJ. Aliskiren reduces sympathetic nerve activity and blood pressure in chronic kidney disease patients. Nephrol Dial Transplant 2011; 26:2930-2934
29. Siddiqi L, Prakken NH, Velthuis BK, Cramer MJ, Oey PL, Boer P, et al. Sympathetic activity in chronic kidney disease patients is related to left ventricular mass despite antihypertensive treatment. Nephrol Dial Transplant 2010; 25:3272-3277
30. Siddiqi L, Blankestijn PJ. Sympathetic activity and clinical outcome in dialysis patients. Hypertension 2009; 54:e8
31. Neumann J, Ligtenberg G, Klein IH, Boer P, Oey PL, Koomans HA, et al. Sympathetic hyperactivity in hypertensive chronic kidney disease patients is reduced during standard treatment. Hypertension 2007; 49:506-510
32. Zilch O, Vos PF, Oey PL, Cramer MJ, Ligtenberg G, Koomans HA, et al. Sympathetic hyperactivity in haemodialysis patients is reduced by short daily haemodialysis. J Hypertens 2007; 25:1285-1289
33. Grassi G, Bertoli S, Seravalle G. Sympathetic nervous system: Role in hypertension and in chronic kidney disease. Curr Opin Nephrol Hypertens 2012; 21:46-51
34. Grassi G, Seravalle G, Ghiadoni L, Tripepi G, Bruno RM, Mancia G, et al. Sympathetic nerve traffic and asymmetric dimethylarginine in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6:2620-2627
35. Tanner RM, Calhoun DA, Bell EK, Bowling CB, Gutierrez OM, Irvin MR, et al. Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol 2013; 8:1583-1590
36. Van Zuilen AD, Blankestijn PJ, Van Buren M, ten Dam MA, Kaasjager KA, Ligtenberg G, et al. Quality of care in patients with chronic kidney disease is determined by hospital specific factors. Nephrol Dial Transplant 2010; 25:3647-3654
37. Van Zuilen AD, Blankestijn PJ, Van Buren M, ten Dam MA, Kaasjager KA, Ligtenberg G, et al. Hospital specific factors affect quality of blood pressure treatment in chronic kidney disease. Neth J Med 2011; 69:229-236
38. Wenzel RR, Spieker L, Qui S, Shaw S, Luscher TF, Noll G. I1-imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives. Hypertension 1998; 32:1022-1027
39. Neumann J, Ligtenberg G, Oey L, Koomans HA, Blankestijn PJ. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-Treated chronic renal failure. J Am Soc Nephrol 2004; 15:2902-2907
40. Barretto AC, Santos AC, Munhoz R, Rondon MU, Franco FG, Trombetta IC, et al. Increased muscle sympathetic nerve activity predicts mortality in heart failure patients. Int J Cardiol 2009; 135:302-307
41. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311:819-823
42. Gerson MC, McGuire N, Wagoner LE. Sympathetic nervous system function as measured by I-123 metaiodobenzylguanidine predicts transplant-free survival in heart failure patients with idiopathic dilated cardiomyopathy. J Card Fail 2003; 9:384-391
43. Kasama S, Toyama T, Sumino H, Kumakura H, Takayama Y, Minami K, et al. Prognostic value of cardiac sympathetic nerve activity evaluated by [123I]m-iodobenzylguanidine imaging in patients with ST-segment elevation myocardial infarction. Heart 2011; 97:20-26
44. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105:1354-1359
45. Cice G, Ferrara L, DAndrea A, DIsa S, Di BA, Cittadini A, et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: A prospective, placebo-controlled trial. J Am Coll Cardiol 2003; 41:1438-1444
46. Azevedo ER, Kubo T, Mak S, Al-Hesayen A, Schofield A, Allan R, et al. Nonselective versus selective beta-Adrenergic receptor blockade in congestive heart failure: Differential effects on sympathetic activity. Circulation 2001; 104:2194-2199
47. Penne EL, Neumann J, Klein IH, Oey PL, Bots ML, Blankestijn PJ. Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment. J Nephrol 2009; 22:208-215
48. Vonend O, Marsalek P, Russ H, Wulkow R, Oberhauser V, Rump LC. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens 2003; 21:1709-1717
49. Bechir M, Enseleit F, Chenevard R, Luscher TF, Noll G. Effect of losartan on muscle sympathetic activity and baroreceptor function in systemic hypertension. Am J Cardiol 2005; 95:129-131
50. Krum H, Lambert E, Windebank E, Campbell DJ, Esler M. Effect of angiotensin II receptor blockade on autonomic nervous system function in patients with essential hypertension. Am J Physiol Heart Circ Physiol 2006; 290:H1706-H1712
51. Grassi G, Turri C, DellOro R, Stella ML, Bolla GB, Mancia G. Effect of chronic angiotensin converting enzyme inhibition on sympathetic nerve traffic and baroreflex control of the circulation in essential hypertension. J Hypertens 1998; 16 (12 Pt 1):1789-1796
52. Somsen GA, Van Vlies B, De Milliano PA, Borm JJ, Van Royen EA, Endert E, et al. Increased myocardial [123I]-metaiodobenzylguanidine uptake after enalapril treatment in patients with chronic heart failure. Heart 1996; 76:218-222
53. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Effects of perindopril on cardiac sympathetic nerve activity in patients with congestive heart failure: Comparison with enalapril. Eur J Nucl Med Mol Imaging 2005; 32:964-971
54. Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y, et al. Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure. Heart 2006; 92:625-630
55. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol 2005; 45:661-667
56. Kasama S, Toyama T, Sumino H, Matsumoto N, Sato Y, Kumakura H, et al. Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure. J Nucl Med 2007; 48:1993-2000
57. Wenting GJ, Blankestijn PJ, Poldermans D, Van Geelen J, Derkx FH, Man int Veld AJ, Schalekamp MA. Blood pressure response of nephrectomized subjects and patients with essential hypertension to ramipril: Indirect evidence that inhibition of tissue angiotensin converting enzyme is important. Am J Cardiol 1987; 59:92D-97D.
58. Wallin BG, Sundlof G, Stromgren E, Aberg H. Sympathetic outflow to muscles during treatment of hypertension with metoprolol. Hypertension 1984; 6:557-562
59. Burns J, Mary DA, Mackintosh AF, Ball SG, Greenwood JP. Arterial pressure lowering effect of chronic atenolol therapy in hypertension and vasoconstrictor sympathetic drive. Hypertension 2004; 44:454-458
60. Rahman MA, Hara K, Daly PA, Wigle ED, Floras JS. Reductions in muscle sympathetic nerve activity after long-Term metoprolol for dilated cardiomyopathy: Preliminary observations. Br Heart J 1995; 74:431-436
61. De Matos LD, Gardenghi G, Rondon MU, Soufen HN, Tirone AP, Barretto AC, et al. Impact of 6 months of therapy with carvedilol on muscle sympathetic nerve activity in heart failure patients. J Card Fail 2004; 10:496-502
62. Pellizzer AM, Kamen PW, Esler MD, Lim S, Krum H. Comparative effects of mibefradil and nifedipine gastrointestinal transport system on autonomic function in patients with mild to moderate essential hypertension. J Hypertens 2001; 19:279-285
63. Lindqvist M, Kahan T, Melcher A, Hjemdahl P. Acute and chronic calcium antagonist treatment elevates sympathetic activity in primary hypertension. Hypertension 1994; 24:287-296
64. Lindqvist M, Kahan T, Melcher A, Ekholm M, Hjemdahl P. Long-Term calcium antagonist treatment of human hypertension with mibefradil or amlodipine increases sympathetic nerve activity. J Hypertens 2007; 25:169-175
65. Grassi G, Seravalle G, Turri C, Bolla G, Mancia G. Short-versus longterm effects of different dihydropyridines on sympathetic and baroreflex function in hypertension. Hypertension 2003; 41:558-562
66. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Bolla G, Mancia G. Baroreflex impairment by low sodium diet in mild or moderate essential hypertension. Hypertension 1997; 29:802-807
67. Grassi G, DellOro R, Seravalle G, Foglia G, Trevano FQ, Mancia G. Short-And long-Term neuroadrenergic effects of moderate dietary sodium restriction in essential hypertension. Circulation 2002; 106:1957-1961
68. Menon DV, Arbique D, Wang Z, ms-Huet B, Auchus RJ, Vongpatanasin W. Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. J Clin Endocrinol Metab 2009; 94:1361-1366
69. Raheja P, Price A, Wang Z, Arbique D, ms-Huet B, Auchus RJ, et al. Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. Hypertension 2012; 60:319-325
70. Andersson B, Elam M, Wallin BG, Bjorntorp P, Andersson OK. Effect of energy-restricted diet on sympathetic muscle nerve activity in obese women. Hypertension 1991; 18:783-789
71. Grassi G, Seravalle G, Colombo M, Bolla G, Cattaneo BM, Cavagnini F, et al. Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans. Circulation 1998; 97: 2037-2042
72. Straznicky NE, Grima MT, Lambert EA, Eikelis N, Dawood T, Lambert GW, et al. Exercise augments weight loss induced improvement in renal function in obese metabolic syndrome individuals. J Hypertens 2011; 29:553-564
73. Matsuoka H, Nishida H, Nomura G, Van Vliet BN, Toshima H. Hypertension induced by nitric oxide synthesis inhibition is renal nerve dependent. Hypertension 1994; 23 (6 Pt 2):971-975
74. Nakashima A, Matsuoka H, Yasukawa H, Kohno K, Nishida H, Nomura G, et al. Renal denervation prevents intraglomerular platelet aggregation and glomerular injury induced by chronic inhibition of nitric oxide synthesis. Nephron 1996; 73:34-40
75. Nagasu H, Satoh M, Kuwabara A, Yorimitsu D, Sakuta T, Tomita N, et al. Renal denervation reduces glomerular injury by suppressing NAD(P)H oxidase activity in Dahl salt-sensitive rats. Nephrol Dial Transplant 2010; 25:2889-2898
76. Hamar P, Kokeny G, Liptak P, Krtil J, Adamczak M, Amann K, et al. The combination of ACE inhibition plus sympathetic denervation is superior to ACE inhibitor monotherapy in the rat renal ablation model. Nephron Exp Nephrol 2007; 105:e124-e136
77. Gattone VH, Siqueira TM Jr, Powell CR, Trambaugh CM, Lingeman JE, Shalhav AL. Contribution of renal innervation to hypertension in rat autosomal dominant polycystic kidney disease. Exp Biol Med (Maywood) 2008; 233:952-957
78. Nishimura M, Takahashi H, Yoshimura M. Upregulation of the brain renin-Angiotensin system in rats with chronic renal failure. Acta Physiol (Oxf) 2007; 189:369-377
79. Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995; 25 (4 Pt 2):878-882
80. Odoni G, Ogata H, Viedt C, Amann K, Ritz E, Orth SR. Cigarette smoke condensate aggravates renal injury in the renal ablation model. Kidney Int 2002; 61:2090-2098
81. Rafiq K, Noma T, Fujisawa Y, Ishihara Y, Arai Y, Nabi AH, et al. Renal sympathetic denervation suppresses De novo podocyte injury and albuminuria in rats with aortic regurgitation. Circulation 2012; 125:1402-1413
82. Veelken R, Vogel EM, Hilgers K, Amann K, Hartner A, Sass G, et al. Autonomic renal denervation ameliorates experimental glomerulonephritis. J Am Soc Nephrol 2008; 19:1371-1378
83. Elzinga LW, Rosen S, Burdmann EA, Hatton DC, Lindsley J, Bennett WM. The role of renal sympathetic nerves in experimental chronic cyclosporine nephropathy. Transplantation 2000; 69:2149-2153
84. Kim J, Padanilam BJ. Renal nerves drive interstitial fibrogenesis in obstructive nephropathy. J Am Soc Nephrol 2013; 24:229-242
85. Nagasu H, Satoh M, Fujimoto S, Tomita N, Sasaki T, Kashihara N. Azelnidipine attenuates glomerular damage in Dahl salt-sensitive rats by suppressing sympathetic nerve activity. Hypertens Res 2012; 35:348-355
86. Mulder J, Hokfelt T, Knuepfer MM, Kopp UC. Renal sensory and sympathetic nerves reinnervate the kidney in a similar time-dependent fashion after renal denervation in rats. Am J Physiol Regul Integr Comp Physiol 2013; 304:R675-R682
87. Grisk O, Grone HJ, Rose HJ, Rettig R. Sympathetic reinnervation of rat kidney grafts. Transplantation 2001; 72:1153-1155
88. Kopp UC, Cicha MZ, Smith LA. Dietary sodium loading increases arterial pressure in afferent renal-denervated rats. Hypertension 2003; 42:968-973
89. Lappe RW, Webb RL, Brody MJ. Selective destruction of renal afferent versus efferent nerves in rats. Am J Physiol 1985; 249 (5 Pt 2):R634-R637
90. Liu S, Brejot T, Cressant A, Bacci J, Said G, Tadie M, et al. Reinnervation of hind limb extremity after lumbar dorsal root ganglion injury. Exp Neurol 2005; 196:401-412
91. Milner P, Lincoln J, Corr LA, Aberdeen JA, Burnstock G. Neuropeptide Y in nonsympathetic nerves of the rat: Changes during maturation but not after guanethidine sympathectomy. Neuroscience 1991; 43:661-669
92. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. JAMA 1953; 152:1501-1504
93. Morrissey DM, Brookes VS, Cooke WT. Sympathectomy in the treatment of hypertension; review of 122 cases. Lancet 1953; 1:403-408
94. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: Durability of blood pressure reduction out to 24 months. Hypertension 2011; 57:911-917
95. Krum H, Barman N, Schlaich M, Sobotka P, Esler M, Mahfoud F. Longterm follow-up of catheter-based renal sympathetic denervation for resistant hypertension confirms durable blood pressure reduction. J Am Coll Cardiol 2012; 59 (13 Suppl):E1704
96. Krum H, Schlaich M, Sobotka P, Esler M, Mahfoud F, Böhm M, et al. TCT-12 long-Term follow-up of catheter-based renal denervation for resistant hypertension confirms durable blood pressure reduction. J Am Coll Cardiol 2012; 60 (17 Suppl):B3
97. Krum H, Schlaich MP, Bohm M, Mahfoud F, Rocha-Singh K, Katholi R, et al. Percutaneous renal denervation in patients with treatmentresistant hypertension: Final 3-year report of the Symplicity HTN-1 study. Lancet 2013; 383:622-629
98. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361:932-934
99. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: A multicentre safety and proof-of-principle cohort study. Lancet 2009; 373:1275-1281
100. Hering D, Lambert EA, Marusic P, Walton AS, Krum H, Lambert GW, et al. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension 2013; 61:457-464
101. Brinkmann J, Heusser K, Schmidt BM, Menne J, Klein G, Bauersachs J, et al. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-To-control hypertensive patients: Prospective case series. Hypertension 2012; 60:1485-1490
102. Hart EC, McBryde FD, Burchell AE, Ratcliffe LE, Stewart LQ, Baumbach A, et al. Translational examination of changes in baroreflex function after renal denervation in hypertensive rats and humans. Hypertension 2013; 62:533-541
103. Schlaich MP, Bart B, Hering D, Walton A, Marusic P, Mahfoud F, et al. Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease. Int J Cardiol 2013; 168:2214-2220
104. Hering D, Mahfoud F, Walton AS, Krum H, Lambert GW, Lambert EA, et al. Renal denervation in moderate to severe CKD. J Am Soc Nephrol 2012; 23:1250-1257
105. Mahfoud F, Cremers B, Janker J, Link B, Vonend O, Ukena C, et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension 2012; 60:419-424
106. Prochnau D, Figulla HR, Surber R. Efficacy of renal denervation with a standard EP catheter in the 24-h ambulatory blood pressure monitoring-long-Term follow-up. Int J Cardiol 2012; 157:447-448
107. Prochnau D, Lucas N, Kuehnert H, Figulla HR, Surber R. Catheterbased renal denervation for drug-resistant hypertension by using a standard electrophysiology catheter. EuroIntervention 2012; 7:1077-1080
108. Prochnau D, Lauten A, Busch M, Kuehnert H, Figulla HR, Surber R. Catheter-based radiofrequency ablation therapy of the renal sympathetic-nerve system for drug resistant hypertension in a patient with end-stage renal disease. Int J Cardiol 2012; 154:e29-e30
109. Di DN, De FM, Violo L, Spinelli A, Simonetti G. Renal sympathetic nerve ablation for the treatment of difficult-To-control or refractory hypertension in a haemodialysis patient. Nephrol Dial Transplant 2012; 27:1689-1690
110. Ott C, Schmid A, Ditting T, Sobotka PA, Veelken R, Uder M, et al. Renal denervation in a hypertensive patient with end-stage renal disease and small arteries: A direction for future research. J Clin Hypertens (Greenwich) 2012; 14:799-801
111. Verloop WL, Vink EE, Voskuil M, Vonken EJ, Rookmaaker MB, Bots ML, et al. Eligibility for percutaneous renal denervation: The importance of a systematic screening. J Hypertens 2013; 31:1662-1668
112. Mahfoud F, Ukena C, Schmieder RE, Cremers B, Rump LC, Vonend O, et al. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension. Circulation 2013; 128:132-140
113. Prochnau D, Heymel S, Gobel B, Figulla HR, Surber R. Resistant hypertension: Multivariate predictors of blood pressure response to renal denervation. Int J Cardiol 2013; 168:3130-3132
114. Johansson M, Elam M, Rundqvist B, Eisenhofer G, Herlitz H, Lambert G, et al. Increased sympathetic nerve activity in renovascular hypertension. Circulation 1999; 99:2537-2542
115. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106:1974-1979
116. Leimbach WN Jr, Wallin BG, Victor RG, Aylward PE, Sundlof G, Mark AL. Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure. Circulation 1986; 73:913-919
117. Grassi G, Seravalle G, Quarti-Trevano F, DellOro R, Bolla G, Mancia G. Effects of hypertension and obesity on the sympathetic activation of heart failure patients. Hypertension 2003; 42:873-877
118. Roksnoer LC, Verdonk K, Van Den Meiracker AH, Hoorn EJ, Zietse R, Danser AH. Urinary markers of intrarenal renin-Angiotensin system activity in vivo. Curr Hypertens Rep 2013; 15:81-88
119. Van Den Heuvel M, Batenburg WW, Jainandunsing S, Garrelds IM, Van Gool JM, Feelders RA, et al. Urinary renin, but not angiotensinogen or aldosterone, reflects the renal renin-Angiotensin-Aldosterone system activity and the efficacy of renin-Angiotensinaldosterone system blockade in the kidney. J Hypertens 2011; 29:2147-2155
120. Teixeira MC, Nahas WC, Mazucchi E, Ianhez LE, vid-Neto E. Role of the peripheral renin profile in predicting blood pressure control after bilateral nephrectomy in renal-Transplanted patients. Nephrol Dial Transplant 1998; 13:2092-2097
121. Grassi G, Seravalle G, Quarti-Trevano F, DellOro R, Bombelli M, Cuspidi C, et al. Adrenergic, metabolic, and reflex abnormalities in reverse and extreme dipper hypertensives. Hypertension 2008; 52:925-931
122. Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper MA, Hoy WE. Biomarkers in chronic kidney disease: A review. Kidney Int 2011; 80:806-821
123. Bolignano D, Lacquaniti A, Coppolino G, Donato V, Campo S, Fazio MR, et al. Neutrophil gelatinase-Associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 2009; 4:337-344
124. Liu KD, Yang W, Anderson AH, Feldman HI, Demirjian S, Hamano T, et al. Urine neutrophil gelatinase-Associated lipocalin levels do not improve risk prediction of progressive chronic kidney disease. Kidney Int 2013; 83:909-914
125. Bolignano D, Donato V, Coppolino G, Campo S, Buemi A, Lacquaniti A, et al. Neutrophil gelatinase-Associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis 2008; 52:595-605
126. Speer T, Rohrer L, Blyszczuk P, Shroff R, Kuschnerus K, Krankel N, et al. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity 2013; 38:754-768
127. Hubens LE, Verloop WL, Joles JA, Blankestijn PJ, Voskuil M. Ischemia and reactive oxygen species in sympathetic hyperactivity states: A vicious cycle that can be interrupted by renal denervation?. Curr Hypertens Rep 2013; 15:313-320
128. Pruijm M, Hofmann L, Vogt B, Muller ME, Piskunowicz M, Stuber M, et al. Renal tissue oxygenation in essential hypertension and chronic kidney disease. Int J Hypertens 2013; 2013:696598
129. Michaely HJ, Metzger L, Haneder S, Hansmann J, Schoenberg SO, Attenberger UI. Renal BOLD-MRI does not reflect renal function in chronic kidney disease. Kidney Int 2012; 81:684-689
130. Chinushi M, Izumi D, Iijima K, Suzuki K, Furushima H, Saitoh O, et al. Blood pressure and autonomic responses to electrical stimulation of the renal arterial nerves before and after ablation of the renal artery. Hypertension 2013; 61:450-456
131. Persu A, Scavee C, Staessen JA, Blankestijn PJ. Electric nerve stimulation to monitor the efficacy of renal denervation. Hypertension 2013; 61:288-289
132. Pokushalov E, Romanov A, Corbucci G, Artyomenko S, Baranova V, Turov A, et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol 2012; 60:1163-1170
133. Tsioufis C, Papademetriou V, Dimitriadis K, Tsiachris D, Thomopoulos C, Park E, et al. Catheter-based renal sympathetic denervation exerts acute and chronic effects on renal hemodynamics in swine. Int J Cardiol 2013; 168:987-992
134. Ott C, Janka R, Schmid A, Titze S, Ditting T, Sobotka PA, et al. Vascular and renal hemodynamic changes after renal denervation. Clin J Am Soc Nephrol 2013; 8:1195-1201
135. Reddy S, Kumar P, Prasad K. Histomorphometric and sympathetic innervation of the human renal artery: A cadaveric study. Urol Ann 2011; 3:141-146
136. Blankestijn PJ. Sympathetic hyperactivity-A hidden enemy in chronic kidney disease patients. Perit Dial Int 2007; 27 (Suppl 2): S293-S297
137. De Jager RL, Blankestijn PJ. Pathophysiology I: The kidney and the sympathetic nervous system. EuroIntervention 2013; 9 (Suppl R): R42-R47
138. Vink EE, Bots ML, Blankestijn PJ. Renal denervation as therapy for hypertension: Potentials and unanswered questions. Eur J Prev Cardiol 2013; 20:980-991.